Creative Biolabs, a biotechnology research service provider, has announced the expansion of its complement assay service portfolio, aiming to support pharmaceutical and biotechnology companies in advancing complement-targeted therapeutics. The new services provide researchers with analytical solutions for evaluating complement pathway activity, therapeutic mechanisms, and candidate performance during preclinical development.
The complement system is a critical part of the immune response, and dysregulation is linked to numerous diseases, making it a target for drug development. However, researchers face challenges due to the complexity of complement pathways, which require specialized assays for accurate evaluation. Creative Biolabs' expanded offerings address these challenges by providing customizable assays that generate reproducible data to guide development decisions.
Among the newly highlighted services is the C3b deposition assay, which measures C3b deposition, a key marker in the complement cascade. This assay supports the characterization of complement-targeting antibodies, proteins, and other therapeutic candidates by providing quantitative data on pathway regulation and biological activity. Another offering, the hemolytic inhibition assay, evaluates a candidate's ability to inhibit complement-mediated cell lysis, enabling functional comparisons under defined conditions.
Additionally, Creative Biolabs offers individual components activity tests, which allow detailed analysis of specific complement proteins. These tests are designed to support mechanism studies and pathway investigations, helping researchers understand how therapeutics interact with the complement system.
The expansion reflects Creative Biolabs' commitment to complement-focused research, combining scientific expertise with customized assay solutions. By providing reliable testing methods, the company aims to help researchers generate actionable data for candidate selection and optimization, potentially reducing the time and resources needed for drug development.
For organizations involved in complement therapeutics, these expanded services could streamline early-stage research and improve the efficiency of preclinical evaluations. As the field of complement-targeted drugs grows, access to robust assay platforms becomes increasingly important for translating scientific discoveries into viable therapies.
Researchers interested in these services can learn more at Creative Biolabs' complement therapeutics page.
